By mitigating airway hyperreactivity, reducing the levels of inflammatory cytokines (IL-4, IL-5 and IL-13) involved in the Th2 immune response, and enhancing Treg immune regulation (IL-10 and TGF-β1), hydrogen therapy has emerged as a promising adjunct strategy in asthma management. The gene discussed is IL13; the disease is asthma.